Business Context and Reporting Period
This Form 8-K was filed by Rexahn Pharmaceuticals, Inc. on February 26, 2016. The filing reports the entry into a material definitive agreement for a registered direct offering of equity securities. Note: The request metadata references "Opus Genetics, Inc.," but the filing text explicitly identifies the registrant as Rexahn Pharmaceuticals, Inc.
Key Financial Metrics and Transaction Details
- Gross Proceeds: $5,000,000 from the sale of 15,625,000 shares of common stock and warrants.
- Offering Price: $0.32 per unit (one share + warrant for 0.75 shares).
- Warrant Terms (Investor): Warrants exercisable for up to 11,718,750 shares at $0.42 per share; exercisable after six months; expire five years from initial exercise date.
- Placement Agent Fees: 6% of gross proceeds ($300,000) plus $30,000 in expenses.
- Placement Agent Warrants: 781,250 shares (5% of shares sold) with an exercise price of $0.40 per share.
- Estimated Net Proceeds: Approximately $4,500,000 after deducting fees and expenses (excluding warrant exercise proceeds).
- Closing Date: Expected on or about March 2, 2016.
Material Changes
The filing does not provide comparative financial data (revenue, profit, or cash flow) against prior periods. The material change reported is the execution of the Securities Purchase Agreement and the Engagement Letter, which will result in a significant increase in cash liquidity upon closing and an increase in the company's outstanding share count.
Outlook, Risks, and Contingencies
- Contingency: The transaction is subject to the satisfaction of customary closing conditions.
- Dilution: The offering involves the issuance of new shares and warrants, which will dilute existing shareholders. The investor warrants and placement agent warrants have exercise prices ($0.42 and $0.40, respectively) higher than the offering price ($0.32).
- Regulatory Status: The investor shares and warrants are issued pursuant to a prospectus supplement under an effective shelf registration (Form S-3). The placement agent warrants are issued under Section 4(a)(2) exemption.
Investor Verification Checklist
- Verify the actual closing date and confirmation of the $5 million gross proceeds receipt.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants or restrictions on the use of proceeds.
- Confirm the impact of the new share issuance on the fully diluted share count and earnings per share.
- Check subsequent filings for any changes to the offering terms or delays in closing.